Fortrea Holdings (FTRE) Operating Income (2022 - 2026)
Fortrea Holdings (FTRE) reported Operating Income of -$3.4 million for Q1 2026, up 99.35% on a YoY basis from -$1.7 million in Q1 2025, and up 75.0% quarter-over-quarter from -$13.6 million in Q4 2025.
Fortrea Holdings (FTRE) Operating Income (2022 - 2026) Analysis & Trends
Fortrea Holdings has reported Operating Income for 5 years, with the latest figure at -$3.4 million in Q1 2026.
- For the quarter ending Q1 2026, Operating Income rose 99.35% year-over-year to -$3.4 million; the trailing twelve-month figure through Mar 2026 stood at -$355.9 million (up 44.79% YoY), and the FY2025 full-year result was -$872.6 million, down 438.97% from the prior year.
- Operating Income for Q1 2026 stood at -$3.4 million, up from -$13.6 million in the prior quarter.
- The five-year high for Operating Income was $71.2 million in Q2 2022, with the low at -$520.1 million in Q1 2025.
- Historically, Operating Income has averaged -$53.2 million across 5 years, with a median of -$11.1 million in 2025.
- Annual changes were most pronounced in 2025 — Operating Income plunged 1290.64% — and 2026, when it soared 99.35%.
- Fortrea Holdings' Operating Income stood at $14.3 million in 2022, then plunged by 267.83% to -$24.0 million in 2023, then sank by 131.67% to -$55.6 million in 2024, then soared by 75.54% to -$13.6 million in 2025, then jumped by 75.0% to -$3.4 million in 2026.
- The last three Operating Income figures came in at -$3.4 million (Q1 2026), -$13.6 million (Q4 2025), and -$8.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -32.68 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.82 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -15.76 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -65.83 Mn |
| 10 | Fortrea Holdings | 1.43 Bn | 1.28 Bn | 123.60 Mn | -3.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.40 Mn |
| Dec 31, 2025 | -13.60 Mn |
| Sep 30, 2025 | -8.60 Mn |
| Jun 30, 2025 | -330.30 Mn |
| Mar 31, 2025 | -520.10 Mn |
| Dec 31, 2024 | -55.60 Mn |
| Sep 30, 2024 | -18.00 Mn |
| Jun 30, 2024 | -50.90 Mn |
| Mar 31, 2024 | -37.40 Mn |
| Dec 31, 2023 | -24.00 Mn |
| Sep 30, 2023 | 10.30 Mn |
| Jun 30, 2023 | 31.60 Mn |
| Mar 31, 2023 | 14.10 Mn |
| Dec 31, 2022 | 14.30 Mn |
| Sep 30, 2022 | 68.90 Mn |
| Jun 30, 2022 | 71.20 Mn |